Get our latest article On a Collision Course - FDA Clinical Investigator Disclosure and Open Payments.
FDA's requirements for clinical investigator disclosure and the Open Payments requirements are at odds in many ways. Published in the September 2016 Life Science Compliance Update, this article explores those differences and what might be done to remedy the situation.
21 August - 20 November 2017 (Online) - Dr. Whitelaw will be co-teaching Health Care Compliance Skills offered by Mitchell Hamline's Health Law Institute. This 3 credit course is offered as part of the Health Care Compliance Certification program.
6-8 November 2017 (Washington, D.C.) - WCG will be attending PCF's Eighteenth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum. Dr. Whitelaw will be on a panel discussing the Compliance and Ethics Considerations in R&D.
30 November - 1 December (Philadelphia, PA) - WCG will be attending CBI's conference on Due Diligence for Life Sciences M&A, Partnerships and Divestitures at which Dr. Whitelaw will participate on a panel discussing the topic of Navigating Third Party Agreement Pitfalls.
Our Custom Compliance Services
The Whitelaw Compliance Group focuses on small to medium-sized pharmaceutical and medical device companies. Our specialty is taking a blank sheet of paper and delivering an affordable, efficient, effective, custom tailored compliance program for our clients. Whether it be medical devices, pharmaceuticals or research and development, we've built it, run it and done it. As a result, we know what works and what doesn't. There simply is no substitute for hands-on experience.
To learn more about how we can help you, please dial +1-215-275-1556 to contact us today.
Presentations & Papers
PRESENTATION: Industry at a Crossroads: Legal and Ethical Considerations of Selling Pharmaceuticals in 2016 given at Mitchell Hamline's Health Law Institute
New Approaches: Focused Monitoring for Smaller Companies
WEBINAR: Transforming Medical Affairs with fact-based solutions and improved compliance
MAKING THE CASE: The Imperative for Life Sciences Companies to Integrate Corporate Compliance and Quality Compliance
INTRODUCTION TO WHITELAW COMPLIANCE GROUP